← Library
Exenatide
FDA ApprovedSince 2005
Also known as Byetta, Bydureon
Function
Primary
Type 2 Diabetes
Mechanism
GLP-1 receptor agonist — augments glucose-dependent insulin secretion, reduces appetite, slows gastric emptying.
Evidence
Clinical RCT (Phase III)
Research
Phase III DURATION program
Dosing
Range
5–10 mcg (IR); 2 mg/week (ER)
Frequency
BID (IR); Weekly (ER)
Route
Subcutaneous
Cycling
Continuous, no cycling.
Benefits
- ·HbA1c reduction ~0.8–1.5%
- ·Modest weight loss
- ·Weekly formulation convenience
Risks
- ·Pancreatitis
- ·Renal impairment caution
- ·Injection site nodules (ER)
- ·GI effects
Contraindications
- ·MTC / MEN-2
- ·Severe renal impairment (CrCl <30)
- ·Severe GI disease
Regulatory
FDA-Approved Rx
Functional Groups
Cited Works
- Buse JB et al. Exenatide once weekly vs twice daily (DURATION-1). Lancet. 2008;372:1240.source